DANONE (BSN.DE) Stock Fundamental Analysis

Europe Frankfurt Stock Exchange FRA:BSN • FR0000120644

71.78 EUR
+0.02 (+0.03%)
Last: Feb 5, 2026, 07:00 PM
Fundamental Rating

5

Overall BSN gets a fundamental rating of 5 out of 10. We evaluated BSN against 67 industry peers in the Food Products industry. While BSN has a great profitability rating, there are quite some concerns on its financial health. BSN has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • BSN had positive earnings in the past year.
  • BSN had a positive operating cash flow in the past year.
  • In the past 5 years BSN has always been profitable.
  • In the past 5 years BSN always reported a positive cash flow from operatings.
BSN.DE Yearly Net Income VS EBIT VS OCF VS FCFBSN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

1.2 Ratios

  • BSN has a better Return On Assets (4.20%) than 62.69% of its industry peers.
  • BSN has a Return On Equity of 11.59%. This is in the better half of the industry: BSN outperforms 67.16% of its industry peers.
  • The Return On Invested Capital of BSN (6.83%) is better than 64.18% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BSN is in line with the industry average of 7.31%.
  • The last Return On Invested Capital (6.83%) for BSN is above the 3 year average (6.38%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 4.2%
ROE 11.59%
ROIC 6.83%
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
BSN.DE Yearly ROA, ROE, ROICBSN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • The Profit Margin of BSN (6.72%) is better than 73.13% of its industry peers.
  • BSN's Profit Margin has been stable in the last couple of years.
  • BSN has a better Operating Margin (13.25%) than 79.10% of its industry peers.
  • BSN's Operating Margin has declined in the last couple of years.
  • With an excellent Gross Margin value of 50.47%, BSN belongs to the best of the industry, outperforming 83.58% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
Industry RankSector Rank
OM 13.25%
PM (TTM) 6.72%
GM 50.47%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
BSN.DE Yearly Profit, Operating, Gross MarginsBSN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BSN is creating some value.
  • The number of shares outstanding for BSN has been increased compared to 1 year ago.
  • Compared to 5 years ago, BSN has less shares outstanding
  • Compared to 1 year ago, BSN has an improved debt to assets ratio.
BSN.DE Yearly Shares OutstandingBSN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
BSN.DE Yearly Total Debt VS Total AssetsBSN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 2.47 indicates that BSN is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • BSN has a Altman-Z score of 2.47. This is comparable to the rest of the industry: BSN outperforms 56.72% of its industry peers.
  • BSN has a debt to FCF ratio of 5.07. This is a neutral value as BSN would need 5.07 years to pay back of all of its debts.
  • BSN has a Debt to FCF ratio of 5.07. This is in the better half of the industry: BSN outperforms 70.15% of its industry peers.
  • A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
  • BSN has a Debt to Equity ratio of 0.83. This is in the lower half of the industry: BSN underperforms 71.64% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF 5.07
Altman-Z 2.47
ROIC/WACC1.06
WACC6.45%
BSN.DE Yearly LT Debt VS Equity VS FCFBSN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • BSN has a Current Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.95, BSN is not doing good in the industry: 71.64% of the companies in the same industry are doing better.
  • BSN has a Quick Ratio of 0.95. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BSN has a Quick ratio (0.78) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 0.95
Quick Ratio 0.78
BSN.DE Yearly Current Assets VS Current LiabilitesBSN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

4

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 4.47% over the past year.
  • BSN shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.17% yearly.
  • Looking at the last year, BSN shows a small growth in Revenue. The Revenue has grown by 0.54% in the last year.
  • Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%

3.2 Future

  • Based on estimates for the next years, BSN will show a small growth in Earnings Per Share. The EPS will grow by 6.09% on average per year.
  • The Revenue is expected to grow by 2.86% on average over the next years.
EPS Next Y7.53%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
EPS Next 5Y6.09%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y2.86%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BSN.DE Yearly Revenue VS EstimatesBSN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 10B 20B 30B
BSN.DE Yearly EPS VS EstimatesBSN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3 4

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 19.19, which indicates a rather expensive current valuation of BSN.
  • The rest of the industry has a similar Price/Earnings ratio as BSN.
  • The average S&P500 Price/Earnings ratio is at 27.92. BSN is valued slightly cheaper when compared to this.
  • With a Price/Forward Earnings ratio of 17.21, BSN is valued on the expensive side.
  • BSN's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 27.78. BSN is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 19.19
Fwd PE 17.21
BSN.DE Price Earnings VS Forward Price EarningsBSN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • BSN's Enterprise Value to EBITDA ratio is in line with the industry average.
  • Based on the Price/Free Cash Flow ratio, BSN is valued a bit cheaper than the industry average as 65.67% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 17.05
EV/EBITDA 10.33
BSN.DE Per share dataBSN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
  • BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.55
PEG (5Y)N/A
EPS Next 2Y7.18%
EPS Next 3Y7.53%

6

5. Dividend

5.1 Amount

  • BSN has a Yearly Dividend Yield of 3.25%. Purely for dividend investing, there may be better candidates out there.
  • BSN's Dividend Yield is a higher than the industry average which is at 2.76.
  • Compared to an average S&P500 Dividend Yield of 1.83, BSN pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.25%

5.2 History

  • The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
BSN.DE Yearly Dividends per shareBSN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

  • BSN pays out 74.99% of its income as dividend. This is not a sustainable payout ratio.
  • BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
BSN.DE Yearly Income VS Free CF VS DividendBSN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B
BSN.DE Dividend Payout.BSN.DE Dividend Payout, showing the Payout Ratio.BSN.DE Dividend Payout.PayoutRetained Earnings

DANONE

FRA:BSN (2/5/2026, 7:00:00 PM)

71.78

+0.02 (+0.03%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)10-07
Earnings (Next)02-20
Inst Owners54.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap48.91B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts75.33
Price Target81.08 (12.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.25%
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.29%
PT rev (3m)2.41%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.43%
EPS NY rev (3m)-0.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.16%
Valuation
Industry RankSector Rank
PE 19.19
Fwd PE 17.21
P/S 1.79
P/FCF 17.05
P/OCF 12.72
P/B 3.08
P/tB N/A
EV/EBITDA 10.33
EPS(TTM)3.74
EY5.21%
EPS(NY)4.17
Fwd EY5.81%
FCF(TTM)4.21
FCFY5.87%
OCF(TTM)5.64
OCFY7.86%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.55
PEG (5Y)N/A
Graham Number44.26
Profitability
Industry RankSector Rank
ROA 4.2%
ROE 11.59%
ROCE 12.02%
ROIC 6.83%
ROICexc 8.36%
ROICexgc 50.58%
OM 13.25%
PM (TTM) 6.72%
GM 50.47%
FCFM 10.49%
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0.83
Debt/FCF 5.07
Debt/EBITDA 2.71
Cap/Depr 77.72%
Cap/Sales 3.57%
Interest Coverage 23.53
Cash Conversion 78.8%
Profit Quality 156.01%
Current Ratio 0.95
Quick Ratio 0.78
Altman-Z 2.47
F-Score8
WACC6.45%
ROIC/WACC1.06
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.53%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
EPS Next 5Y6.09%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y2.86%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.93%
EBIT Next 3Y14.73%
EBIT Next 5Y10.6%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%

DANONE / BSN.DE FAQ

What is the fundamental rating for BSN stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.


What is the valuation status for BSN stock?

ChartMill assigns a valuation rating of 4 / 10 to DANONE (BSN.DE). This can be considered as Fairly Valued.


How profitable is DANONE (BSN.DE) stock?

DANONE (BSN.DE) has a profitability rating of 7 / 10.


What is the earnings growth outlook for DANONE?

The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.53% in the next year.


Is the dividend of DANONE sustainable?

The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 74.99%.